T cells

[Nature Communications] Investigators used single-cell RNA sequencing to identify and profile SARS-CoV-2-reactive T cells from COVID-19 patients.

[Nature Immunology] Researchers showed that the epigenetic state of exhaustion was largely irreversible, even after curative therapy. Analysis of chromatin accessibility in HCV- and HIV-specific responses identified a core epigenetic program of exhaustion in CD8+ T cells, which underwent only limited remodeling before and after resolution of infection.

[Nature Reviews Immunology] Mucosal vaccines offer the potential to trigger robust protective immune responses at the predominant sites of pathogen infection. The identification of safe and effective mucosal adjuvants allied to innovative antigen discovery and delivery strategies is key to advancing mucosal vaccines.

[Scientific Reports] Investigators developed a sandwich ELISA to detect prostate-specific membrane antigen on small extracellular vesicles (EVs) using T-cell immunoglobulin domain and mucin domain-containing protein 4 as a capture molecule for EVs and to evaluate its diagnostic potential in urologic malignancies.

[Eureka Therapeutics, Inc.] Eureka Therapeutics, Inc. announced the initiation of a Phase I/II clinical trial of ECT204, a GPC3 targeting ARTEMIS® T-cell therapy for the treatment of hepatocellular carcinoma, the predominant type of liver cancer.

[EMBO Reports] Investigators used whole-genome analyses to show that the transcriptional program and epigenetic features of Treg cells were attenuated in the absence of Tet2 and Tet3.